JP2021522795A5 - - Google Patents
Info
- Publication number
- JP2021522795A5 JP2021522795A5 JP2020561780A JP2020561780A JP2021522795A5 JP 2021522795 A5 JP2021522795 A5 JP 2021522795A5 JP 2020561780 A JP2020561780 A JP 2020561780A JP 2020561780 A JP2020561780 A JP 2020561780A JP 2021522795 A5 JP2021522795 A5 JP 2021522795A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- item
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666548P | 2018-05-03 | 2018-05-03 | |
| US62/666,548 | 2018-05-03 | ||
| US201862779992P | 2018-12-14 | 2018-12-14 | |
| US62/779,992 | 2018-12-14 | ||
| PCT/US2019/030475 WO2019213446A1 (en) | 2018-05-03 | 2019-05-02 | NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522795A JP2021522795A (ja) | 2021-09-02 |
| JP2021522795A5 true JP2021522795A5 (enExample) | 2022-05-13 |
Family
ID=68386156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561780A Pending JP2021522795A (ja) | 2018-05-03 | 2019-05-02 | ＴＧＦβ−スーパーファミリーのリガンドの新規バインダーおよびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12168683B2 (enExample) |
| EP (1) | EP3788067A4 (enExample) |
| JP (1) | JP2021522795A (enExample) |
| AU (1) | AU2019262143A1 (enExample) |
| CA (1) | CA3099325A1 (enExample) |
| WO (1) | WO2019213446A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12103959B2 (en) | 2018-05-03 | 2024-10-01 | Acceleron Pharma Inc. | Multispecific binders of TGFBeta-superfamily ligands and uses thereof |
| WO2021092079A1 (en) | 2019-11-05 | 2021-05-14 | Acceleron Pharma Inc. | Treatments for systemic sclerosis |
| US20240277807A1 (en) * | 2021-06-11 | 2024-08-22 | Acceleron Pharma Inc. | Actrii proteins and uses thereof |
| CA3232382A1 (en) * | 2021-09-27 | 2023-03-30 | Zoetis Services Llc | Anti- tgf.beta.1,2,3 antibodies and therapeutic uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2449753T3 (es) | 2007-03-19 | 2014-03-21 | National Research Council Of Canada | Proteínas de fusión que comprenden dos dominios de unión tgf-beta |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US10195249B2 (en) | 2012-11-02 | 2019-02-05 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| JP6631865B2 (ja) | 2014-08-11 | 2020-01-15 | 日本化薬株式会社 | ＴＧＦβ阻害機能を持つキメラタンパク質 |
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| CA3039573A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| AU2017338915B2 (en) * | 2016-10-05 | 2024-11-21 | Acceleron Pharma Inc. | TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof |
| CN110036025B (zh) | 2016-10-05 | 2024-03-22 | 阿塞勒隆制药公司 | 变体ActRIIB蛋白及其用途 |
-
2019
- 2019-05-02 US US17/052,783 patent/US12168683B2/en active Active
- 2019-05-02 CA CA3099325A patent/CA3099325A1/en active Pending
- 2019-05-02 EP EP19796602.1A patent/EP3788067A4/en active Pending
- 2019-05-02 WO PCT/US2019/030475 patent/WO2019213446A1/en not_active Ceased
- 2019-05-02 JP JP2020561780A patent/JP2021522795A/ja active Pending
- 2019-05-02 AU AU2019262143A patent/AU2019262143A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/924,487 patent/US20250333477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021522795A5 (enExample) | ||
| EP3218411B1 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
| JP2022523524A5 (enExample) | ||
| US20230348565A1 (en) | Methods of using activin receptor type ii variants | |
| JP2023554500A5 (enExample) | ||
| JP2021175391A5 (enExample) | ||
| CN119569850A (zh) | 激活素受体iia型变体及其使用方法 | |
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| JP2021522793A5 (enExample) | ||
| JP7793774B2 (ja) | メソテリン結合タンパク質及びその使用 | |
| JP2023522799A5 (enExample) | ||
| US20180280474A1 (en) | Treatment of bile acid disorders | |
| JP2022540918A5 (enExample) | ||
| JP2024504923A5 (enExample) | ||
| WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
| CN117295758A (zh) | 包含抗原结合结构域及细胞因子三聚体结构域的融合蛋白 | |
| WO2022226352A1 (en) | Kidney-glomerular targeted immunotherapy | |
| AU2022316521B2 (en) | A fusion protein comprising an antigen binding domain and a cytokine trimer domain | |
| JP2024537397A5 (enExample) | ||
| WO2026037338A1 (zh) | 一种阻断baff、april作用其受体的融合蛋白 | |
| WO2025228408A1 (zh) | Ghr激动型抗体及其应用 | |
| TW202342551A (zh) | 包含抗原結合結構域及細胞因數三聚體結構域的融合蛋白 | |
| CN118119402A (zh) | 工程化抗her2双特异性蛋白 | |
| CA3196077A1 (en) | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof | |
| JP2025524899A (ja) | メソテリン結合タンパク質及びその使用 |